ALK and non-small cell lung carcinoma: Traditionally, the treatment strategy for early-stage ALK-positive NSCLC has been similar to that for NSCLC without oncogenic driver mutations, achieving a 5-year survival rate for stage IIIA NSCLC of only 36% (1).